Stockscreener 앱 받기
23.48
5.76%
-1.435
시간 외 거래:
23.45
-0.025
-0.11%
전일 마감가:
$24.91
열려 있는:
$24.04
하루 거래량:
368.80K
Relative Volume:
0.78
시가총액:
$836.98M
수익:
$154.15M
순이익/손실:
$-33.58M
주가수익비율:
-24.45
EPS:
-0.96
순현금흐름:
$-20.74M
1주 성능:
-2.43%
1개월 성능:
+5.65%
6개월 성능:
-52.74%
1년 성능:
+81.55%
1일 변동 폭
$22.70
$24.33
1주일 범위
$20.85
$25.26
52주 변동 폭
$9.86
$59.23
Harrow Inc Stock (HROW) Company Profile
명칭
Harrow Inc
전화
615.733.4731
주소
102 WOODMONT BLVD, NASHVILLE, CA
HROW을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
23.48 | 836.98M | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
147.00 | 65.57B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.87 | 43.81B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.63 | 43.47B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
12.82 | 14.69B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
278.89 | 12.53B | 2.76B | 1.11B | 898.10M | 22.77 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-06 | 개시 | H.C. Wainwright | Buy |
| 2024-12-04 | 재확인 | B. Riley Securities | Buy |
| 2024-04-11 | 개시 | Craig Hallum | Buy |
| 2022-09-08 | 재개 | B. Riley Securities | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-09-24 | 개시 | Aegis Capital | Buy |
| 2021-07-02 | 개시 | Ladenburg Thalmann | Buy |
모두보기
Harrow Inc 주식(HROW)의 최신 뉴스
Major Dry Eye Treatment Breakthrough: VEVYE Opens Access to 25,000+ Patients with $59 Price Tag - Stock Titan
Where Harrow Stands With Analysts - Benzinga
B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating - MarketScreener
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives By GuruFocus - Investing.com Canada
Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha
Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives - Yahoo Finance
Harrow Health Reports Strong 2024 Financial Performance - TipRanks
Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp (NASDAQ:HROW) - Seeking Alpha
Harrow Health (HROW) Gets a Buy from Craig-Hallum - The Globe and Mail
Harrow (HROW) Q4 Earnings and Revenues Top Estimates - Yahoo Finance
Harrow: Q4 Earnings Snapshot - The Advocate
Harrow Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results - Joplin Globe
Harrow To Report Fourth Quarter and Audited Year-End 2024 Financial Results After Market Close on March 27, 2025 - Business Wire
Harrow Inc. sees $150k stock sale by Opaleye Management - Investing.com
Harrow sees shares increase following drug approval - Nashville Post
Craig-Hallum Reaffirms Their Buy Rating on Harrow Health (HROW) - The Globe and Mail
CMS approves separate reimbursement for Harrow’s TRIESENCE - Investing.com
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL - Business Wire
TRIESENCE Secures Medicare Pass-Through Status for Separate Reimbursement | HROW Stock News - Stock Titan
Harrow Inc (HROW) Shares Up 1.14% on Mar 22 - GuruFocus
Opaleye management sells $148,200 in Harrow, Inc. stock - Investing.com India
What To Expect From Harrow Inc (HROW) Q4 2024 Earnings - GuruFocus
Opaleye Management Inc. Adjusts Stake in Harrow Inc. - GuruFocus
Bank of New York Mellon Corp Has $2.90 Million Stock Holdings in Harrow, Inc. (NASDAQ:HROW) - Defense World
Harrow Inc (HROW) Shares Up 2.97% on Mar 21 - GuruFocus
Opaleye management sells $148,200 in Harrow, Inc. stock By Investing.com - Investing.com South Africa
Harrow: A Name I Am Accumulating (NASDAQ:HROW) - Seeking Alpha
H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains Harrow Health stock Buy rating, $57 target - Investing.com India
Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial - GlobeNewswire Inc.
Harrow stock surges on preliminary Q4 numbers - Nashville Post
Sector Update: Health Care -March 18, 2025 at 08:49 am EDT - Marketscreener.com
Harrow Soars On Preliminary Q4 Results, Revenue Outlook - RTTNews
Why Harrow Shares Are Trading Higher By 23%; Here Are 20 Stocks Moving Premarket - Benzinga India
Harrow Reports Preliminary 2024 Q4 and Full-Year Financial Results, Provides 2025 Guidance and Launches New Initiative - VisionMonday.com
Harrow Inc (HROW) Reports Q4 Revenue Between $65M-$67M, Surpassi - GuruFocus.com
Harrow Completes Transfer of the TRIESENCE® New Drug Application - Business Wire
Harrow Reports Q4 Preliminary Revenue -- Shares Rise After Hours -March 17, 2025 at 04:30 pm EDT - Marketscreener.com
Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance - Business Wire
Harrow Launches VEVYE® Access for All - Business Wire
Harrow Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts - Benzinga
HARROW HEALTH Earnings Preview: Recent $HROW Insider Trading, Hedge Fund Activity, and More - Nasdaq
Harrow shares react modestly to FDA move | Area Stocks - Nashville Post
Harrow Inc (HROW) 재무 분석
매출
순이익
현금흐름
주당 순 이익
7.14%
자본화:
|
볼륨(24시간):